Spain
· Delayed Price · Currency is EUR Oryzon Genomics Statistics
Total Valuation
Oryzon Genomics has a market cap or net worth of EUR 191.54 million. The enterprise value is 202.14 million.
| Market Cap | 191.54M |
| Enterprise Value | 202.14M |
Important Dates
The next estimated earnings date is Friday, May 9, 2025.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Oryzon Genomics has 64.71 million shares outstanding. The number of shares has increased by 5.73% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 64.71M |
| Shares Change (YoY) | +5.73% |
| Shares Change (QoQ) | +1.56% |
| Owned by Insiders (%) | 10.29% |
| Owned by Institutions (%) | 0.35% |
| Float | 54.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 25.89 |
| PB Ratio | 2.19 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -55.15 |
| EV / Sales | 27.47 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.75, with a Debt / Equity ratio of 0.19.
| Current Ratio | 0.75 |
| Quick Ratio | 0.74 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.73 |
Financial Efficiency
Return on equity (ROE) is -4.34% and return on invested capital (ROIC) is -2.82%.
| Return on Equity (ROE) | -4.34% |
| Return on Assets (ROA) | -2.66% |
| Return on Invested Capital (ROIC) | -2.82% |
| Return on Capital Employed (ROCE) | -4.72% |
| Revenue Per Employee | 159,973 |
| Profits Per Employee | -79,683 |
| Employee Count | 46 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 67.11 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +72.97% in the last 52 weeks. The beta is 0.63, so Oryzon Genomics's price volatility has been lower than the market average.
| Beta (5Y) | 0.63 |
| 52-Week Price Change | +72.97% |
| 50-Day Moving Average | 2.39 |
| 200-Day Moving Average | 1.89 |
| Relative Strength Index (RSI) | 51.46 |
| Average Volume (20 Days) | 1,522,032 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oryzon Genomics had revenue of EUR 7.36 million and -3.67 million in losses. Loss per share was -0.06.
| Revenue | 7.36M |
| Gross Profit | 7.06M |
| Operating Income | -4.58M |
| Pretax Income | -5.57M |
| Net Income | -3.67M |
| EBITDA | -4.43M |
| EBIT | -4.58M |
| Loss Per Share | -0.06 |
Balance Sheet
The company has 5.62 million in cash and 16.21 million in debt, giving a net cash position of -10.59 million or -0.16 per share.
| Cash & Cash Equivalents | 5.62M |
| Total Debt | 16.21M |
| Net Cash | -10.59M |
| Net Cash Per Share | -0.16 |
| Equity (Book Value) | 87.04M |
| Book Value Per Share | 1.35 |
| Working Capital | -2.99M |
Cash Flow
| Operating Cash Flow | -5.69M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 95.89%, with operating and profit margins of -62.26% and -49.81%.
| Gross Margin | 95.89% |
| Operating Margin | -62.26% |
| Pretax Margin | -75.71% |
| Profit Margin | -49.81% |
| EBITDA Margin | -60.25% |
| EBIT Margin | -62.26% |
| FCF Margin | n/a |
Dividends & Yields
Oryzon Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.73% |
| Shareholder Yield | -5.73% |
| Earnings Yield | -1.91% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |